Frontier Medicines To Present At The 43Rd Annual J.P. Morgan Healthcare Conference
(MENAFN- GlobeNewsWire - Nasdaq) BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the“Company”), a clinical-stage precision medicine company unlocking to advance transformational therapies, today announced that Chris Varma, Ph.D., Frontier's co-founder, chairman, and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare conference on Tuesday, January 14, 2025 at 11:30 a.m. PT.
About Frontier Medicines
Frontier Medicines is a clinical stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically-defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics powered drug discovery engine, the FrontierTM Platform, leverages covalent chemistry and machine learning to unlock hard-to-treat disease causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly-owned precision medicines against the most important drivers of cancer and high-value immunology programs. Our lead candidate, FMC-376, is a dual inhibitor of ON+OFF KRASG12C. FMC-376 is a potential best-in-class therapy designed to completely block both forms of the KRAS mutation to overcome the lack of response and resistance seen with single-acting KRASG12C inhibitors. For more information, please visit . Follow Frontier on LinkedIn .
Frontier Medicines Contact:
Victoria Fort
SVP, Strategy and Corporate Affairs
...
202.361.0445
MENAFN08012025004107003653ID1109070030
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.